Syremis Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $165M
Overview
Developing precision small-molecule therapies for central nervous system disorders.
Neuroscience
Technology Platform
Focuses on designing selective small molecules that precisely modulate specific CNS targets and neural pathways.
Funding History
1Total raised:$165M
Series A$165M
Opportunities
Potential to create transformative, better-tolerated treatments for major neuropsychiatric and neurodegenerative diseases.
Risk Factors
High risk of clinical failure due to the complexity of the brain and challenges in demonstrating efficacy in trials.
Competitive Landscape
Faces intense competition in the CNS drug development arena from both startups and large pharma.